Subscribe
Subscribe for the Newsletter
Mobile Navigation
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Experience
Market Research
Directory
Close
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Biologics - Large Molecule
Sort By
Newest First
Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.
Explore
About Us
Nice Insight
That's Nice
Reach Our Team
Contact Us
Advertise
LinkedIn
My Account
Login
Sign up
Subscribe for the newsletter
© 2026 PHARMA'S ALMANAC. All rights reserved.
Privacy Policy
Terms And Conditions
(478)
1 / 24
AI-Optimized CLD
From Screening to Design: Can Production Cell Lines Become Programmable Platforms?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-19
Jul 20, 2026
Drug–Device
Designing Formulations Around Devices Rather Than Vice Versa
Pharma's Almanac
PAO-07-26-PA-04
Jul 7, 2026
Protein Conformation
Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-17
Jul 6, 2026
Cell-Free Synthesis
Cell-Free Biomanufacturing and the Future of Flexible Biologics Production
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-24
Jun 15, 2026
Digital Sampling
Enhancing Quality and Environmental Monitoring Efficiency Through Paperless Sampling
Jiwoon Kim; Neulbit Kim; Hyeonjung Park
Samsung Biologics
PAO-06-26-CL-01
Jun 10, 2026
Protein Engineering
Exponential Advances in Protein Engineering
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-06-26-PA-04
Jun 8, 2026
BsAbs
Why Bispecific Antibody Architecture Is a CMC Decision
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-01
Jun 2, 2026
NGIB
Rethinking Fermentation: Halophiles and the Next Generation of Industrial Biotechnology
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-05
May 18, 2026
ADC Engineering
Engineering Antibodies for Precision Payload Delivery
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-04
May 4, 2026
Carbon Footprint
Product Carbon Footprint: Enabling Product-Level Decarbonization in Biopharma
Jimin Han
Samsung Biologics
PAO-05-26-CL-01
Apr 30, 2026
PAT
Real-Time Insight in Biologic Manufacturing: Why PAT Matters for Commercial Scale-Up
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-PA-11
Apr 16, 2026
PAT
From Analytical Visibility to Real-Time Control in Biologics Purification
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-PA-10
Apr 15, 2026
Pathfinder
CHO vs. HEK293: Which Expression System Is Better for Biopharmaceutical Production?
Pharma's Almanac
PAO-26-PF-02
Apr 10, 2026
Oral mAbs
Oral Delivery of Monoclonal Antibodies: The Pursuit Continues
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-04-26-PA-05
Apr 7, 2026
Neuro CMC
Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-PA-03
Apr 3, 2026
Ultra-Small-Scale
When Commercial Manufacturing Serves Dozens, Not Thousands
David Alvaro, Ph.D.
Pharma's Almanac
PAO-02-26-NI-11
Feb 13, 2026
Facility Flexibility
Experience and Flexibility Ensure Accelerated Development and Security of Supply
Jordi Ruano
HIPRA Biotech Services
PAO-01-26-CL-04
Feb 3, 2026
Process
Re-Imagining Process Understanding in Mammalian Systems
Dave Briggs, Ph.D.
Avid Bioservices
PAO-01-26-CL-06
Jan 27, 2026
Biologics
State of the Industry 2026 Virtual Panel: Biologics
Nice Insight
PAO-26-SOTI-03
Jan 26, 2026
Tech Transfer
Seamless Technology Transfer: Accelerating Biologics from Drug Substance to Drug Product
Sangkyu Hwang; Brian Junhyuk Heo
Samsung Biologics
PAO-01-26-CL-05
Jan 20, 2026
1 / 24